LGM
SLRN

Logos Global Management’s ACELYRIN SLRN Stock Holding History

Logos Global Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,250,000
Closed -$9.32M – 70
2023
Q4 		$9.32M Buy
+1,250,000
New +$10.7M 0.87% 26

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Logos Global Management's SLRN Position: Q1 2024 in Review

Logos Global Management sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 1,250,000 shares — an estimated $9.32M sold.

Logos Global Management first reported a position in SLRN in Q4 2023 and held it in 1 quarter. The position peaked at $9.32M in Q4 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

  • Logos Global Management reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
  • Logos Global Management sold 1,250,000 ACELYRIN shares in Q1 2024, an estimated $9.32M.
  • Logos Global Management first reported a position in ACELYRIN in Q4 2023 and held it in 1 quarter.
  • Logos Global Management's ACELYRIN position peaked at $9.32M in Q4 2023.
  • 109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.